Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03551522 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)
A Phase 2 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 181
- Enrollment target
NCT03551522 is a Phase 2 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 181 participants.
The verdict
NCT03551522, a Phase 2 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 181 participants
- Enrollment target
Study Summary
A Phase 2, Double-Blind (DB), Randomized, Placebo-Controlled Study Followed by an Open-Label Extension Period to Evaluate the Activity of Seladelpar in Subjects with Nonalcoholic Steatohepatitis (NASH) OLE phase was not analyzed due to the early termination of the study
Interventions
- DRUG Placebos
- DRUG Seladelpar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2018-04-30 |
| Est. Completion | 2020-08-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03551522
The ClinicalTrials.gov registry entry for NCT03551522 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 181 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT03551522 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03551522 about?
NCT03551522 is a clinical study titled "A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)". A Phase 2, Double-Blind (DB), Randomized, Placebo-Controlled Study Followed by an Open-Label Extension Period to Evaluate the Activity of Seladelpar in Subjects with Nonalcoholic Steatohepatitis (NASH) OLE phase was not analyzed due to the early termination of the study
What is the current status of trial NCT03551522?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 181 participants. The study started on 2018-04-30. Estimated completion is 2020-08-10.
What interventions are being tested in trial NCT03551522?
The interventions under investigation include: Placebos (DRUG), Seladelpar (DRUG).
Who is sponsoring clinical trial NCT03551522?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.